Cannabis in Adults with Cancer

Publication Date: March 13, 2024

Key Points

Key Points

  • Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use.
  • This guideline provides strategies for open, nonjudgmental communication between adults with cancer and clinicians about the use of cannabis and cannabinoids.
  • Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial.
  • Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting (CINV) when added to guideline-concordant antiemetic regimens.
    • Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain.

Treatment

...atment...

...ommunication and Education

...1.1Health systems and clinicians,...

...1.2Given the high prevalence of canna...

...1.3When adults with cancer use cannabis and/o...


...er Treatment...

...2.1Clinicians should recommend against use...

...dation 2.2Clinicians should recommend...


...ent-related Toxicity, Symptoms, and Quality of...

...mendation 3....

...dronabinol and nabilone] (EB, , M, Weak...

...:CBD extract] (EB, , L, Weak)3499376...

...on 3.2Outside of a clinical trial, clinician...

...commendation 3.3Evidence remains insufficient t...


...ble 1. Taking an In-depth History o...


...y of Recommendations Pertaining to Use...


...eneral Safety AwarenessHaving trouble...


...1. Endocannabinoid System...


...that cancer clinical trials are vital to in...